At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 635 enrolled
Drug / intervention
Tadalafildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Postmarketing Surveillance Study: A Randomized, Open-Label, 3-Month Interventional Study of Tadalafil Effectiveness (2.5 mg and 5 mg) and Long-Term Safety Administered Once Daily in Chinese Men With Erectile Dysfunction
In Brief
A Phase 4 clinical trial evaluating Tadalafil for Erectile Dysfunction. Completed, enrolled 635 participants across 17 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and effectiveness of the study drug, taken once daily, known as tadalafil in Chinese participants with erectile dysfunction (ED). The study will last about up to 25 months for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErectile Dysfunction
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartOct 2014
Primary CompletionMay 2016
Study CompletionMay 2017
TodayJul 2026
First PostedAug 25, 2014
Enrollment StartOct 1, 2014
Primary CompletionMay 1, 2016
Study CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.9 years ago
Interventions
Tadalafildrug
Administered orally